This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Twitter Trounces Wall St. With Real-Time Take on Achillion Pharma's Hep C News

Stocks in this article: ACHN GILD IDIX VRTX ABBV MRK ENTA

NEW HAVEN, Conn. ( TheStreet) -- Hey Wall Street, Twitter is kicking your ass.

Friday night after the close, Achillion Pharmaceuticals (ACHN) halted trading in its stock and announced two important updates to its hepatitis C drug development program. Twitter's biotech investor community mobilized instantly to dissect and analyze Achillion's announcement in real time.

Let me emphasize that last part again because it's revolutionary: Twitter provided real-time, accurate and insightful analysis of Achillion's stock-moving news. Where were Wall Street's sell-side analysts in the seconds and minutes after Achillion's news broke? Still warming up their Bloomberg terminals and trying to roust somnolent compliance officers for permission to call or email clients.

Permission? How quaint... and pathetic. Wall Street's research investment model is dying. Meanwhile, Twitter and its facility for fostering institutional quality analysis -- technical and fundamental -- in real time is ascendant.

Follow along to see how biotech investors on Twitter were all over Friday's Achillion hepatitis C drug announcement.

It started on Thursday.

Achillion closed Friday's regular trading session down 15 cents to $7.24. The stock was halted in the after-hours session at 4:14 pm ET.

Next came the speculation and predictions while we waited for Achillion's announcement.

Achillion issued its press release at 4:30 pm ET. The FDA refused to lift a clinical hold on the company's experimental hepatitis C drug sovaprevir. Interim results from a study combining sovaprevir and another Achillion drug, ACH-3012, in treatment-naive genotype 1 hepatitis C patients were also released.

The first reaction to Achillion's announcement hit the Twitter feed within seconds.

I was 1 minute behind! Typing a few extra words cost me precious seconds.

Not all of the initial Twitter reactions were correct, but that's to be expected. Most were.

Two minutes after Achillion's announcement, Twitter's biotech community kicks the analysis into high gear.

At 4: 43 pm ET -- 13 minutes after Achillion's press release -- Twitter is discussing the impact of the news on the rest of the hepatitis C drug market -- Idenix Pharma (IDIX), Vertex Phama (VRTX), Merck (MRK), Gilead Sciences (GILD), Abbvie (ABBV), Enanta Pharma (ENTA).

Achillion reopened for trading at 5 pm ET.

Deutsche Bank analyst Alethia Young sent an email to clients on the Achillion news at 6:03 pm ET. By then, biotech investors on Twitter were already enjoying Friday night beers and cocktails.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs